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Abstract  
Objective: The objective of the study is to explore preferences of gastroenterologists 
for biosimilar drugs in Crohn’s Disease and reveal trade-offs between the perceived 
risks and benefits related to biosimilar drugs.  
Method: Discrete choice experiment was carried out involving 51 Hungarian 
gastroenterologists in May, 2014. The following attributes were used to describe 
hypothetical choice sets: 1) type of the treatment (biosimilar/originator) 2) severity of 
disease 3) availability of continuous medicine supply 4) frequency of the efficacy 
check-ups. Multinomial logit model was used to differentiate between three attitude 
types: 1) always opting for the originator 2) willing to consider biosimilar for 
biological-naïve patients only 3) willing to consider biosimilar treatment for both types 
of patients. Conditional logit model was used to estimate the probabilities of choosing a 
given profile. 
Results: Men, senior consultants, working in IBD center and treating more patients are 
more likely to willing to consider biosimilar for biological-naïve patients only. 
Treatment type (originator/biosimilar) was the most important determinant of choice for 
patients already treated with biologicals, and the availability of continuous medicine 
supply in the case biological-naïve patients. The probabilities of choosing the biosimilar 
with all the benefits offered over the originator under current reimbursement conditions 
are 89% vs 11% for new patients, and 44% vs 56% for patients already treated with 
biological.  
Conclusions: Gastroenterologists were willing to trade between perceived risks and 
benefits of biosimilars. The continuous medical supply would be one of the major 
benefits of biosimilars. However, benefits offered in the scenarios do not compensate 
3 
 
for the change from the originator to the biosimilar treatment of patients already treated 
with biologicals.  
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Introduction 
 
The biosimilar infliximab drugs (brand names Remsima
TM
 and Inflectra
TM
) is the first 
biosimilar monoclonal antibody medicines in chronic inflammatory conditions 
approved by the European Medicine Agency in 2013 [1,2]. These drugs were registered 
under the same conditions as the originator infliximab
2
 for the treatment of six adult 
conditions and in two pediatric indications. Nevertheless, randomized clinical trials 
(RCT) have been carried out only in two adult rheumatic disorders: a non-inferiority 
study in rheumatoid arthiritis (RA) and another in anklyosing spondylitis (AS) [1,2]. 
These studies did not find significant differences either in efficacy or in safety between 
the originator and the biosimilar substance [3,4]
3
. In the other four conditions 
(Ulcerative Colitis - UC, Crohn’s Disease - CD, Psoriatic Arthritis - PsA, and Psoriasis) 
no RCTs were carried out with the biosimilar agent.
4
 Due to the lack of evidence from 
RCTs, physicians are cautious, and have several concerns about using biosimilars in 
these indications. Since clinical guidelines often do not contain recommendations 
regarding the use of biosimilar products [5], the use of biosimilars strongly depend own 
individual risk perception of clinicians. 
 
                                                          
2
 According to the definition of EMA, ’A biosimilar medicine is a medicine which is similar to a 
biological medicine that has already been authorized (the ‘biological reference medicine’).  
The active substance of a biosimilar medicine is similar to that of the biological reference medicine. 
Biosimilar and biological reference medicines are used in general at the same dose to treat the same 
disease.’ 
3
 Also, two meta-analysis indirectly compared the infliximab-biosimilar to other biological agents 
indicated in RA and AS, and found no differences between biological treatments [1,2] 
4
 Evidence is though accumulating from observational studies and a cross-over study is underway in 
inflammatory bowel disease (IBD) [6]. 
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On the other hand, biosimilar drugs are substantially (20% to 70%) cheaper than the 
originator [7]. The availability of cheaper treatment options means that from the same 
budget more patients could be treated. For example a previous budget impact study in 
RA showed that in three years, that the number of patients on biological therapy could 
be increased by 7-10% in the Central and Eastern European region, if cost-savings were 
spent on reimbursement of additional biological treatment [8]. At present, access to 
biologicals is rather unequal, up to 96-fold difference were found in access to biological 
treatments even across the EU member states of the CEE countries [7]. Biosimilars have 
the potential to improve this situation, by providing access to a larger number of 
patients, and/or allow to start the biological treatment in less severe health states, which 
would contribute to substantial health gains [8]. 
Thus, health care actors (physicians as well as payers) face trade-off between perceived 
risks and potential benefits when making decisions about the use of biosimilar 
medicines. So far, little is known about preferences of health care actors. Although the 
penetration of biosimilars to clinical practice and consequently potential benefits related 
to their use might strongly depend on these preferences. Previous studies examined 
clinicians’ attitudes to biosimilars did not consider these trade-offs, and did not connect 
the risks with potential benefits [9,10].  
This study aimed to reveal Hungarian gastroenterologists’ preferences for originator vs. 
biosimilar treatment in Crohn’s Disease (CD) using discrete choice experiment (DCE), 
where respondents are faced with hypothetical scenarios of treatment options. The 
objective of this study is to explore the willingness of clinicians to use biosimilar drugs 
for biological agent naïve and already treated patients with CD in exchange for certain 
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benefits in loosening the conditions of the reimbursement guideline, namely 1) starting 
the treatment already in less severe health state than allowed by the current 
reimbursement guideline, 2) ensuring the continuous medicine supply or 3) changing 
the frequency of the efficacy check-up interventions required by the reimbursement 
guideline.  
 
Methods 
The study was carried out in Hungary, one of the Central and Eastern European 
countries where the biosimilar medicines have been first marketed for IBD. In Hungary, 
since May 2014, “newly initiated biological therapy with infliximab must be undertaken 
with a biosimilar antibody. A mandatory switch is not recommended; however, 
relapsers should only be treated with a biosimilar (or adalimumab) if more than a year 
has passed since the termination of the previous biological therapy”. [7] 
Data were collected among gastroenterologists, who participated on the 56th Meeting of 
the Hungarian Gastroenterology Society in May, 2014. Altogether 200 questionnaires 
were distributed. The participation was voluntary. The questionnaire included a detailed 
explanation of the research. Informed consent was signed. Ethical approval was 
obtained (Semmelweis University Regional and Institiutional Committee of Science and 
Research Ethics, Nr.: 103/2014). 
Discrete choice experiment (DCE) is a widely used stated preference method to evaluate 
preferences (see more in: [11, 12]. In DCE respondents are faced with a hypothetical 
scenarios and choice sets of goods and services characterized by certain attributes. The 
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profiles differ from each other in the levels of their attributes. The respondents are asked 
to choose the profile that they prefer the most. In this way we are able to elicit the 
preferences for health care services, to examine the effect of the changes of attribute 
levels on the respondents’ choice. In a clinical setting DCE is often used to reveal 
patients’ and clinicians’ preferences for treatment options [11]. DCE has been used in a 
study by Johnson and colleagues to evaluate trade-offs between treatment efficacy and 
potential adverse events in CD [13,14], and by Lichtenstein and colleagues to reveal 
patients’ preferences for treatment characteristics in CD [15]. 
For the purposes of our study, 4 attributes (all with two levels) were selected based on 
the current reimbursement guideline and discussions with clinicians to describe the 
hypothetical scenarios:  
1) the type of treatment: originator/biosimilar 
2) the disease severity level required for the initiation of biological treatment: Can 
be applied for patients with (Crohn’s Disease Activity Index5 
 (CDAI)>300)/ Can be applied for patients with (CDAI>220)) 
3) the availability of continuous  medicine supply: Due to the shortage of medicine 
excess of the budget, the treatment can be delayed by 3-4 weeks/ The medicine 
supply is continuous. 
4) Frequency of efficacy check-ups required by the reimbursement guideline: Once 
a year/ Once in two years 
                                                          
5
 The Crohn’s disease activity index (CDAI) is a numerical calculation derived from the sum of 
products from a list of 8 items, and multiplied by weighting factors for each item to define the 
severity of “disease activity” in patients with CD [16]. 
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According to the clinicians involved in the interviews, starting the biological treatment 
in a less severe health state would be a potential benefit of using biosimilar treatments. 
At the moment, CD patient with CDAI<300 are not entitled for reimbursed biological 
treatment. Budget constrains were also mentioned by the clinicians as a potential 
problem for the medicine supply, which can lead to delays in the treatment of patients. 
The frequency of efficacy check-ups was also considered as a potentially important 
attribute. According to the current reimbursement guideline the treatment cannot be 
continued without an efficacy check with endoscope or MR in every 12 month. The 
endoscope examination besides being invasive might be painful and uncomfortable for 
patients, who would rather avoid this type of procedure; however the access to MR as 
an alternative technique might be limited or delayed due to the waiting lists.  
Seven choice sets were presented to the respondents. In all the choice sets, the base 
scenario described the current situation under the conditions of the current 
reimbursement guideline with originator treatment (i.e. can be applied if the CDAI>300, 
treatment might be delayed by 3-4 weeks due to the lack of supply, efficacy check-up 
once a year). The alternative scenarios described biosimilar treatments with varying 
benefits offered (i.e. relaxed the reimbursement conditions step-by-step). Clinicians 
were asked to choose the preferred treatment option for 1) biological agent naïve 
patients (hereinafter “new patients”) and 2) patients currently treated with originator 
biological drug (hereinafter “treated patients”). Table 1 presents an example for the 
choice set. The questionnaire was piloted with 5 clinicians. 
INSERT TABLE 1 HERE 
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The questionnaire contained additional items regarding social-demographic and 
professional features of the gastroenterologists (age, gender, doctoral degree, position, 
membership in scientific committees) and their practices (whether it is settled in the 
capital, in the center of the county, or other town/or village; type of the practice: out-
patient or inpatient clinic; whether it is an IBD center – where patients can be treated 
with biologicals, the number of CD patients treated by the physician, the number of CD 
patients treated with biological). A multiple choice question regarding clinicians’ 
attitude to biosimilar treatments was also included in the questionnaire with the 
following options: a) have no concerns about the use of biosimilar medicines in CD, and 
these can be applied under the same conditions as the originator b) have some concerns 
using biosimilars and c) biosimilar medicines should not be applied in CD at all. Those, 
who indicated concerns, were asked whether these concerns are related to a) efficacy, b) 
safety, c) both or d) other reason. 
Two types of analysis were carried out to explore the preferences of physicians. First, 
multinomial logit model was used to differentiate between three attitude groups 
formulated based on the choices of clinicians: 1) those who always opt for the originator 
treatment for both new and treated patients (hereinafter: the “No biosimilar” group) , 2) 
those who are not willing to change the ongoing originator biological treatment for 
biosimilar therapy but consider the biosimilar option for new patients groups (i.e. opted 
for the biosimilar option for new patients at least in one choice set), hereinafter: the 
“Biosimilar for new patients only” group; 3) those who are willing to consider the 
biosimilar option for both new and treated patients in exchange for the benefits offered 
in the DCE, hereinafter the “Biosimilar” group. The following covariates were used in 
the regressions analysis to predict group memberships: clinicians’ age, gender, position 
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(chief physician or not), having a scientific membership, having a PhD degree, the 
settlement of the practice (Budapest or not), whether the practice is an IBD center in 
Hungary, the number of CD patients treated. The effects of the covariates on the 
predicted probabilities of belonging to the three groups were calculated. 
Second, conditional logit model was used to analyze the DCE. The effect of changing 
attribute levels were calculated on the probabilities of choosing a given profile, while 
other attributes remain constant. Odds ratios (ratio of the probability of choosing a 
given profile over the probability of choosing the base option) are presented. Separate 
analysis was carried out for new patients and patients already treated. We carried out the 
analysis for the total sample (including traders and non-traders), and also for traders 
only. 
Results  
Fifty-one gastroenterologists filled in the survey. The average age of the respondents 
was 47.6 years (range: 26-74). About 65% of the respondents were female, 41% of them 
had senior consultant position, 55% had a PhD degree and 41% had scientific 
committee membership. Altogether, 65% of them are working in an IBD center. About 
22 respondents had a practice in Budapest. Regarding the type of the practice, 5 
clinicians worked in an out-patient care, 21 in inpatient care and 24 in both out-patient 
and inpatient care, while one clinician did not answer this question. Clinicians were 
treating on average 24.7 CD patients on average (range: 0-100) and the rate of patients 
receiving biological treatment was 24%.  
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Ten clinicians (19.6%) indicated that he/she has absolutely no concerns using 
biosimilars in CD, as the EMA registered them under the same conditions as the 
originators. Thirty-three (64.7%) clinicians indicated some concerns about using 
biosimilars in CD (two had concerns about efficacy, 7 had concerns about safety and 21 
had concerns both with efficacy and safety). Six (11.8%) clinicians said they do not 
support the use of biosimilars in CD at all due to the lack of evidence from randomized 
controlled trials in this indication. Two respondents did not answer this question.  
Based on their choices, clinicians were categorized in three attitude groups: four 
clinicians (7.8%) belonged to the “No biosimilar” group, 19 (37.3%) to the “Biosimilar 
to new patients only” group and 27 (52.9%) to the “Biosimilar” group. One clinician 
chose biosimilar treatment in at least one choice set for already treated patients, but 
never chose the biosimilar option in the case of new patients. Being a unique case, this 
observation was excluded from this analysis. 
According to the results multinomial logit model
6
 characteristics such as 1) being male, 
2) being a senior consultant, 3) having practice in Budapest, 4) working in IBD center 
significantly increases the probability of belonging to the “Biosimilar to new patients 
only” group by 32, 58, 43 and 48 percentage points respectively. The probability of 
belonging to this group decreases with age (marginal effect 3 percentage points), but 
increases with the number of CD patients (marginal effect of 2 percentage points). Not 
being a senior consultant and working in a practice outside Budapest increases the 
probability of belonging to the “Biosimilar” group by 58 and 52 percentage points, 
                                                          
6 Model characteristics: Number of observations: 49; Wald Chi2=54.95 (p<0.001); Pseudo R2= 0.4905. 
Detailed results are presented in Supplementary Table 2. 
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respectively. Being older, as well as treating fewer patients significantly increases the 
probability of belonging to this group (marginal effects are 3 and 2 percentage points). 
Being female increases the probability of belonging to the “No biosimilar” group 
(marginal effect of 56 percentage points). Detailed results of the  
Comparing the regression results with the answers to the multiple choice question 
regarding concerns about the use of biosimilars, we find that in the “Biosimilar group” 
26% of clinicians indicated no concerns regarding the use of biosimilars, compared to 
16% in the “Biosimilar to new patients only” and  0% in the “No biosimilar” group.  
The estimated coefficients of the conditional logit model are presented in Table 2. 
According to the results, for new patients, the continuity of the medicine supply was the 
most important treatment attribute, followed by the severity of the disease and the 
frequency of efficacy check-ups. The type of the treatment (biosimilar or originator) 
was found not to be a significant determinant of choice. For patients already treated 
with biologicals, the type of the treatment was the most important factor, followed by 
the continuity of the medicine supply. Severity had positive but insignificant, and the 
frequency of check-ups had negative but insignificant coefficients.  
INSERT TABLE 2 HERE 
Predicted probabilities of choosing biosimilar medicine over the originator treatment 
under the current reimbursement conditions (i.e. can be applied when the CDAI>300, 
treatment might be delayed by 3-4 weeks due to the lack of supply, efficacy check-up 
once a year) were calculated (see Table 2). For new patients the estimated probability of 
choosing the originator treatment over the biosimilar, when all the attributes describe 
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the current reimbursement situation, is 60%. For patients already treated with 
biologicals this probability is higher, 74%. The probabilities of choosing the biosimilar 
with all the benefits offered over the originator in the current situation are 89% vs 11% 
for new patients and 44% vs 56% for patients already treated with biologics.  
Discussion 
In this experiment we identified important determinants of different attitudes towards 
biosimilars.  
We found that opinion leaders of the profession (i.e. men, senior consultants who are 
treating more CD patients and working in IBD centers) have strong concerns of 
changing the originator treatment to biosimilar, but willing to consider starting the 
treatment of new patients with biosimilar.  
We also explored what benefits could potentially compensate for the perceived risk of 
using biosimilars. Our results suggest that clinicians are more willing to apply 
biosimilar treatment for new patients than to change to biosimilar. For patients already 
treated with biologicals, the type of treatment (originator/biosimilar) was the most 
important determinant of treatment choice and the benefits offered in the choice sets 
could not compensate for the change from the originator to biosimilar treatment. On the 
other hand, physicians had less concerns choosing biosimilar treatment option for new 
(biological-naïve) patients in exchange for the benefits offered in the choice sets. 
We found that for gastroenterologist, the continuity of the medical supply is one of the 
major benefits of using biosimilar treatment. This finding is especially important in low 
income countries such as Hungary, where continuous medicine supply might not be 
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available due to the providers’ budget constraints. Apparently there is a heterogeneity 
regarding the preferences for the frequency of efficacy check-ups. The negative but 
insignificant coefficient for patients already treated with biological suggests that some 
clinicians have concerns about the less frequent efficacy check-ups when changing the 
originator to biosimilar. However for new patients, less frequent efficacy check-ups are 
significantly preferred. 
In the literature, preferences of clinicians have been relatively widely studied for small 
molecular generic drugs (e.g. [17,18]), nevertheless limited number of studies examined 
attitude towars biosimilars, although it seems to be a more complex and debated issue. 
So far only one previous study has presented results on the attitude of 
gastroenterologists regarding biosimilar medicines from a web-based survey with 307 
IBD specialists [9]. According to their results, less than 10% of clinicians would replace 
the originator with a biosimilar for a patient already under treatment, while 25% would 
consider interchangeability only for new prescriptions. Another, Canadian survey with 
81 rheumatologists explored physicians’ attitudes towards biosimilars and found that 
about one-third of the clinicians were unlikely or very unlikely to offer a biosimilar 
treatment to a biologic naïve patient as initial therapy, even though evidence from RCTs 
are available in this indication [10]. These studies presented only descriptive results and 
did not analyze determinants of attitude types, and benefits which might compensate for 
the risks of using biosimilar treatments. 
In our study similar share of clinicians (77%) indicated concerns regarding the use of 
biosimilars in CD in the multiple-choice question. However, a relatively higher share of 
clinicians was willing to consider treatments with biosimilar in the DCE task when 
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certain benefits (with regards to the reimbursement conditions) were offered in the 
choice sets to compensate for the risk of using of biosimilar drugs. Thus, we learned 
from this experiment that clinicians are more willing to use biosimilar medicines if they 
and their patients are the beneficiaries of the cost-savings (i.e. are allowed to use the 
savings to ensure continuous medicine supply, treat more patients, or patients in less 
severe conditions). However in real practice, this might not be the case, which results in 
higher resistance towards biosimilars. 
When interpreting the results, we have to be aware, that in Hungary it is now mandatory 
to treat all new and relapsing patients with a biosimilar infliximab product (or 
adalimumab), otherwise the treatment is not reimbursed. Thus, the current practice 
might have an influence on preferences as well. It should be noted also that the 
relatively small sample size might limit the robustness of the statistical analysis. 
Furthermore, we have to account for the potential of sample selection bias, as those who 
agreed to participate in the survey might have different preferences compared to those 
who refused to participate. 
In conclusion we have identified important determinants of different attitudes towards 
biosimilars with availability of continuous medical supply and less prescription 
restrictions as the major possible benefits of using biosimilar treatment. In contrast, 
gastroenterology specialists have strong concerns of changing the originator treatment 
to biosimilar, but they are willing to consider starting the treatment of new patients with 
biosimilar. We believe that our study contributes to the literature with new and 
important evidence on the preferences of clinicians of using biosimilar medicine, as 
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these preferences may directly or indirectly influence treatment practices and choice of 
medication, and consequently the budget impact of biosimilars. 
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Table 1 Example for a choice set 
Type of the treatment Originator 
 
Biosimilar 
Indication Can be applied for patients with 
(CDAI>300)  
Can be applied for patients 
with (CDAI>300)   
Supply of medicine Due to the shortage of medicine 
excess of the budget, the treatment 
can be delayed by 3-4 week 
The medicine supply is 
continuous. 
Frequency of efficacy 
check-up 
Once a year Once a year 
For new patients: 
 
For treated patients: 
A) I start therapy with the originator 
B) I start the therapy with the biosimilar treatment, if I find the 
situation appropriate. 
A) I continue to use the originator agent 
B) I change the therapy with originator to biosimilar treatment, if I 
find the situation appropriate. 
22 
 
Table 2 Results of the conditional logit model and predicted probabilities of choosing biosimilar medicine over the originator treatment under 
the current financial conditions 
Note: * p<0.1, ** p<0.05, *** p<0.001. OR= 
odds ratio. 
a 
Pr=Probability: estimated 
probability of choosing the profile when the 
alternative biosimilar scenario is the base 
scenario (i.e. originator with no benefits) 
  
 
Type: 
Biosimilar 
Benefit: less 
severe 
condition 
Benefit: 
secure 
supply 
Benefit: 
Efficacy 
check-up 
less 
frequent 
Number of 
observations 
Wald 
Chi
2 
 
Pseudo 
 R
2
 
Regression results 
New Patients 
Coefficient (Std.err) 
-0,40 
(0,31) 
0,86*** 
(0,24) 
1,15*** 
(0,24) 
0,53** 
(0.22) 
708 
27.23 
(p<0.001) 
0.20 
Treated Patients 
Coefficient (Std.err) 
-1,04*** 
(0,31) 
0,09 
(0,12) 
0,74*** 
(0,18) 
-0,02 
(0,15) 
706 
21.99 
(p<0.001) 
0.07 
Estimated probabilities 
Scenarios 
Type: 
Biosimilar 
Benefit: less 
severe 
condition 
Benefit: 
secure 
supply 
Benefit: 
Efficacy 
check-up 
less 
frequent 
New Patients Treated Patients 
Pr
a
 
OR = 
Pr(alt) 
Pr(base) 
Pr
a
 
OR = 
Pr(alt) 
Pr(base) 
Base scenario  NO NO NO NO     
Biosimilar scenario 1 YES NO NO NO 40% 0.67 26% 0.35 
Biosimilar scenario 2 YES YES NO NO 61% 1.58 28% 0.39 
Biosimilar scenario 3 YES NO YES NO 68% 2.11 43% 0.74 
Biosimilar scenario 4 YES NO NO YES 53% 1.14 26% 0.35 
Biosimilar scenario 5 YES YES YES NO 83% 4.97 45% 0.82 
Biosimilar scenario 6 YES YES NO YES 78% 3.59 42% 0.73 
Biosimilar scenario 7 YES NO YES YES 73% 2.69 28% 0.38 
Biosimilar scenario 8 YES YES YES YES 89% 8.48 44% 0.80 
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Supplementary Table 1 Descriptive statistics of the sample 
Variable N (%) Mean 
(St. Dev.) 
Range 
[Min-Max] 
Clinicians’ characteristics 
Age  51-(100%) 47.6 (11.4) [26-74] 
Years of practice  48 (94.1%) 19.0 (11.3) [0-45] 
Gender=Female  33 (64.7%) - - 
Head=Yes 21 (41.2%) - - 
Scientific committee member=Yes 21 (41.2%) - - 
PhD=Yes 28 (54.9%) - - 
Practice 
Settlement of practice  
Budapest 
County capital 
Other town/city 
Multiple 
 
21 (41.2%) 
23 (45.1%) 
4 (7.8%) 
3 (5.9%) 
- - 
Type of the Practice 
Out-patient care 
Inpatient 
Both 
Missing 
 
5 (9.8%) 
21 (41.2%) 
24 (47.1%) 
1(2.0%) 
- - 
Practice: Mainly hepatology 5 (9.8%) - - 
Practice: Mainly gastroenterology 33 (64.7%) - - 
Practice: Mainly IBD  19 (37.3%) - - 
IBD centrum=Yes 33 (64.7%) - - 
Number of CD patient  50 (98.0%) 24.7 (26.8) [0-100] 
Number of CD patients treated with biologicals 50 (98.0%) 5.9 (10.1) [0-46] 
Risk perception regarding the use of biosimilars 
No concerns 
Concerns regarding the safety or efficacy 
Should not be applied 
Missing 
 
10 (19.6%) 
33 (64.7%) 
6 (11.8%) 
2 (3.9%) 
- - 
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Supplementary Table 2 Results of the multinomial logit model - Marginal effects and predicted probabilities of belonging to three groups 
 
“No 
biosimilar” 
“Biosimilar 
to new 
patients 
only” 
“Biosimila
r” 
“No biosimilar” 
“Biosimilar to 
new patients 
only” 
“Biosimilar” 
Predicted probability of 
belonging to the group 
- - - 0,03 0,32 0,65 
  Group characteristics Regression: Marginal effects 
Clinician 
Female = yes 3 (75%) 6 (32%) 9 (33%) 0,56** (0,24) -0,32* (0,18) -0,24 (0,27) 
Age (years) 45.5 (11.6) 45.8 (8.1) 48.6 (11.4) -0,001 (0,004) -0,03** (0,01) 0,03** (0,01) 
Senior consultant = yes 2 (50%) 9 (47%) 9  (33%) 0,0001 (0,04) 0,58** (0,25) -0,58** (0,24) 
Scientific Committee = yes 2 (50%) 7 (37%) 12 (44%) 0,18 (0,13) -0,36 (0,28) 0,18 (0,30) 
PhD = yes 2 (50%) 11 (58%) 14 (52%) -0,01 (0,04) -0,29 (0,36) 0,30 (0,35) 
Practice       
Budapest = yes 2 (50%) 10 (53%) 9 (33%) 0,09 (0,07) 0,43* (0,26) -0,52** (0,24) 
Ibd centrum = yes 1 (25%) 17 (90%) 15 (56%) -0,18 (0,17) 0,48*** (0,15) -0,29 (0,21) 
Number of CD patients 35.5 (43.9) 39.9 (31.7) 13.5 (12.8) 0,001 (0,001) 0,02*** (0,01) -0,02*** (0,01) 
   Model characteristics 
Number of obs 4 19 27 49
+
 
Wald chi2(8) - - - 54.95 
Prob > chi2 - - - <0.001 
Pseudo R2 - - - 0.4905 
Note: * p<0.1, ** p<0.05, *** p<0.001; One observation was excluded as not belonging to any of the three groups, and for one clinician the number of 
CD patients were missing. “No biosimilar” group refers to those who always opt for the originator treatment for both new and treated patients. 
“Biosimilar for new patients only” group refers to those who are not willing to change the ongoing originator biological treatment for biosimilar therapy 
but consider the biosimilar option for new patients groups. “Biosimilar” group refers to those who are willing to consider the biosimilar option for both 
new and treated patients in exchange for the benefits offered in the DCE.
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